Publication | Closed Access

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

MedicinePharmacologyPathologyCell DeathBronchial NeoplasmAnti-cancer AgentPhase Iii StudyCancer TreatmentOncologyRadiation OncologyCancer ResearchLung CancerTumor Biology